Roivant Sciences Ltd. (ROIV)
29.06
+0.56
(+1.98%)
USD |
NASDAQ |
Jun 09, 16:00
29.06
0.00 (0.00%)
After-Hours: 20:00
Roivant Sciences Enterprise Value : 17.10B for June 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Centessa Pharmaceuticals Plc | 5.985B |
| Aptorum Group Ltd. | 0.2268M |
| Bicycle Therapeutics Plc | -337.47M |
| Adaptimmune Therapeutics Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 3.302B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 355.74M |
| Revenue (Quarterly) | 2.52M |
| Total Expenses (Quarterly) | -300.47M |
| EPS Diluted (Quarterly) | 0.373 |
| Gross Profit Margin (Quarterly) | 61.98% |
| Earnings Yield | -1.73% |
| Normalized Earnings Yield | -4.235 |